Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) ≥18.5 kg/m\^2 and ≤32.0 kg/m\^2~* Under evaluation for treatment of chronic hepatitis C virus (HCV)~* Chronic compensated, genotype 1 HCV infection~* Treatment-naïve or previously treated and tolerated at least 12 weeks of continuous licensed interferon (including pegylated interferon) and ribavirin combination therapy with at least a partial response, or previously treated with investigational products and/or vaccines, other than HCV nonstructural proteins (NS) NS3/4A protease inhibitors, either alone or in combination with other licensed therapies~* Able to avoid use of anticoagulants, nonsteroidal anti-inflammatory agents and aspirin for at least seven (7) days preceding the initial liver biopsy and continuing throughout the entire study~* Female participants of childbearing potential or male participants with female sexual partners of childbearing potential must agree to use two acceptable methods of birth control from 2 weeks prior to the first dose through at least 6 months after last dose of study drug, or longer if dictated by local regulation~Exclusion criteria:~* Pregnant, lactating, or intending to become pregnant or donate eggs, or intending to donate sperm~* History of stroke, chronic seizures, or major neurological disorder~* Did not achieve a viral response to prior treatment with licensed interferon-based therapy~* Previously treated with an NS3/4A protease inhibitor (investigational or licensed)~* Evidence or history of chronic hepatitis not caused by HCV infection including but not limited to non-HCV viral hepatitis, nonalcoholic steatohepatitis (NASH), drug-induced hepatitis or autoimmune hepatitis~* Clinical or laboratory evidence of cirrhosis or other advanced liver disease~* Decompensated liver disease as indicated by a history of ascites, hepatic encephalopathy, or bleeding esophageal varices~* Diagnosed with or suspected of having hepatocellular carcinoma~* Co-infection with human immunodeficiency virus (HIV)~* Positive hepatitis B surface antigen or other evidence of active hepatitis B infection~* History of gastric bypass surgery or bowel resection~* History of clinically significant uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* History of clinically significant neoplastic disease~* Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL\], wine \[125 mL\], or distilled spirits \[25 mL\]) per day~* Regular user, including use of any illicit drugs, or has a history of drug (including alcohol) abuse within the last 3 months~* Surgery or donation of 1 unit of blood (approximately 500 mL) or participation in another investigational study within a period of 4 weeks prior to the prestudy (screening) visit~* History of multiple and/or severe allergies, or has had an anaphylactic reaction or intolerability to prescription or nonprescription drugs or food

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vaniprevir 600 mg (Type: EXPERIMENTAL): Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
- Vaniprevir 600 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
- Vaniprevir 300 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).